Novartis on the Street: Analysts’ Recommendations in November

In November 2017, Novartis (NVS) submitted a Marketing Authorization Application (or MAA) to the European Medical Agency (or EMA) for Kymriah (tisagenlecleucel) or CTL019 as a treatment for adult individuals with relapsed or refractory DLBCL (diffuse large B-cell lymphoma) who are not eligible for autologous stem cell transplant (or ASCT).

Novartis also submitted an MAA for CTL019 as a treatment for individuals aged under 25 years old with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL).

Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.” On November 13, 2017, Novartis had a consensus 12-month consensus target price of $93.00, which represents a ~12.1% return on investment over the next 12 months.

Notably, the Vanguard FTSE Europe ETF (VGK) invests ~1.2% of its total portfolio holdings in Novartis.

Of the 22 analysts tracking Pfizer (PFE) in November 2017, ~55% recommend some form of “buy.” On November 13, 2017, Pfizer had a consensus 12-month target price of $38.47, which represents a ~9.4% return on investment over the next 12 months.

Of the 20 analysts tracking Merck (MRK) in November 2017, ~50% recommend a “buy.” On November 13, 2017, Merck had a consensus 12-month target price of ~$65.95, which represents a 19.3% return on investment over the next 12 months.

Of the 22 analysts tracking Bristol-Myers Squibb (BMY) in November 2017, ~41% recommend some form of “buy.” Two analysts recommend a “sell” for the stock. On November 13, 2017, Bristol-Myers Squibb had a 12-month consensus target price of $63.24, which represents a ~3.9% return on investment over the next 12 months.